Cities for Better Health Childhood Obesity Prevention Initiative
Launched by NOVO NORDISK A/S · Feb 26, 2025
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The "Cities for Better Health Childhood Obesity Prevention Initiative" is a research study that aims to find out how programs designed to improve children's eating habits and physical activity can help reduce obesity among kids. The study is looking for children aged 6 to 13 years to participate, and it will begin recruiting soon. To join, a child's parent or legal guardian must first provide their consent for their child to be part of the study. This means they need to agree to allow the researchers to collect information related to the child's health and activities.
If your child is selected to participate, they will take part in activities that help researchers learn more about how lifestyle changes can affect health. It's important to note that if a parent does not give consent, or if the child doesn’t want to participate during the study, they cannot be included. The goal of this study is to make a real difference in helping children lead healthier lives, so your involvement could play a significant role in shaping future health programs.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Informed consent obtained by the child's parent or legal guardian before any study-related activities (where study-related activities are defined as any procedure related to recording of data according to the protocol). The specific consent form and procedures for obtaining consent will be outlined by the local project partner.
- • Aged 6-13 years (both 6 and 13 allowed) at the time of signing consent. Deviations from or exceptions to this procedure must be agreed between the research team in the relevant country and the GIP, and are subject to the relevant local ethical amendment procedure. The exception must be due to a scientifically sound rationale and must further consider the following guiding principles: "it must be measurable, it must have marginal utility, it must be meaningful (i.e. linked to the ultimate impact and the primary and/or secondary objective)".
- Exclusion Criteria:
- • - Children will be excluded from the study if their parent(s) do not provide fully informed consent for their data to be collected, if during the measurement day they do not agree to participate, or if the child's parent(s) or legal guardian(s) withdraw their consent for their child participating in the research at any point in line with processes described in local informed consent forms. In communications asking for consent, parents will be prompted to evaluate whether their children have issues with mental incapacity or language barriers that would preclude adequate understanding or cooperation.
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Johannesburg, , South Africa
Madrid, , Spain
Campinas, , Brazil
Mississauga, , Canada
Le Havre, , France
Chiba, , Japan
Campinas, , Brazil
Patients applied
Trial Officials
Clinical Transparency (dept. 2834)
Study Director
Novo Nordisk A/S
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported